Optometry - Journal of the American Optometric Association
Volume 75, Issue 7 , Pages 419-429 , July 2004

Pediatric use of topical ophthalmic drugs

  • Rachel Anastasia Coulter, O.D.

      Affiliations

    • Corresponding Author InformationCorrespondence address: Nova Southeastern University 3200 South University Drive Ft. Lauderdale, Florida 33328.

References 

  1. Cote CJ. Adverse drug reactions and the package insert. Acta Paediatr. 1999;88:925–927
  2. Nahata MC. (May 1997) Licensing of medicines for children in the USA. Paediatric and Perinatal Drug Therapy 1997. http://www.Priory.com/pharmol/lomfcitu.html. Last accessed April 3, 2002.
  3. Metry DW, Hebert AA. Topical therapies and medications in the pediatric patient. Pediatr Clin North Am. 2000;47(4):867–876
  4. Shelton DL. (June 12, 2000). Pace picks up in pediatric studies. Amednews.com. http://www.ama-assn.org/sci-pubs/amnews/pick_00/hlsa0612.html. Last accessed April 3, 2003.
  5. Modern regulatory environment shaped by pediatric pharmacology. Cited from Brown University Child and Adolescent Psychopharmacology Update 2002;4(5):l, 2-3. Medscape. http://www.medscape.com/viewarticle/433244_print. Last accessed April 4, 2003).
  6. Zenk KE. Challenges in providing pharmaceutical care to pediatric patients. Am J Hosp Pharm. 1994;51:688–694
  7. Meadows M. Drug research and children. FDA Consum. 2003;37(2):36
  8. Miller HI. The FDA drug approval process: focus on pediatric labeling [Letter to the editor]. Science. 2002;296(5573):1609–1610
  9. Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104:585–590
  10. Wilson JT, Kearns GL, Murphy D, et al. Paediatric labelling requirements: implications for pharmakinetic studies. Clin Pharmacokinet. 1994;24:308–325
  11. Turner ST, Longworth A, Nunn AJ, et al. Unlicensed and off label drug use in paediatric wards: prospective study. Br Med J. 1998;316:343–345
  12. Buck ML. (2000). The FDA Modernization Act of 1997: Impact on pediatric medicine. Cited from Pediatr Pharm 2000; 6(12):2000. Medscape. http://www.medscape.com/viewarticle/410910. Last accessed September 27, 2003.
  13. Bonetta L. Pediatric study of medicines becomes mandatory. Nat Med. 2000;6:1069
  14. Pediatric clinical trials are on the rise as new law goes into effect. (August 9, 2000). Medscape Medical News. http://www.medscape.com/viewarticle/412078. Last accessed September 28, 2003.
  15. Nordenberg T. Pediatric Drug Studies. FDA Consum. 1999;33(4):23–28
  16. Cohen SN. The pediatric pharmacology research unit (PPRU) network and its role in meeting pediatric labeling needs. Pediatrics. 1999;104:644–645
  17. Karst KR. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry. Am Univ Law Rev. 2000;49:739–772
  18. FDA draft sets 50,000 pediatric prescription mentions/year threshold for research list. FDC Reports “The Pink Sheet”1998;60(12):11-2.
  19. FDA mandatory pediatric labeling rule would apply to first indication for NMEs, marketed products with wide use or important benefits in children. FDC Reports “The Pink Sheet” 1997;59(33):3-4.
  20. HHS Identifies drugs for pediatric testing and announces FY 2003 and FY 2004 funding. News release (January 21, 2003) Health and Human Services, Washington, D.C. http://www.hhs.gov/news. Last accessed October 27, 2003.
  21. Dove A. FDA in a quandary over Pediatric Rule. Nat Med. 2002;8(6):541–542
  22. Safety-related labeling for pediatric drugs. Cited from Drug Benefit Trends 1999;11(1):11. Medscape. http://www.medscape.com/viewarticle/416823. Last accessed September 29, 2003.
  23. Otto A. Industry heeds FDA call to add pediatric info to drug labels. Cited from Pharmacy Today 2001. 7(2). Medscape. http://www.medscape.com/viewarticle/4066801. Last accessed September 29, 2003.
  24. Plummer J. (May 2000). FDA's Pediatric Rule restricts access to medicine. Consumers’ Research Magazine. www.consumeralert.org/pubs/research/CRMayOO.html. Last accessed April 3, 2003.
  25. Arshagouni P. (December 23, 2002). Federal court invalidates the FDA Pediatric Rule: AAPS v. FDA. http://www.law.uh.edu/healthlawperspectives/Children/021223Federal.html. Last accessed April 3, 2003.
  26. Association of American Physicians and Surgeons, Inc. v. U.S. Food and Drug Administration, 2002, U.S. Dist LEXIS 19689 http://www/law.uh.edu/healthlawperspectives (D.D.C., October 17, 2002).
  27. Barclay L. (November 6, 2002). Court overturns FDA Pediatric Rule: an expert interview with Philip Watson, M.D. Medscape Medical News, http://medscape.com/viewarticle/444180. Last accessed April 3, 2003.
  28. (2003). Recent court decision invalidating FDA's Pediatric Rule. Biotechnology Industry Organization, http://www.bio.org/reg/pedrule.asp. Last accessed April 3, 2003.
  29. Marshall E. Challenge to FDA's authority may end up giving it more. Science. 2002;296:820–821
  30. Best Pharmaceuticals for Children Act. Public Law 107–109. pll5 Stat. 1408.
  31. Pediatric Pharmacy Administrative Group Committee on Pediatric Pharmacy Practice. Am J Hosp Pharm. 1991;48:2475–2477
  32. Koren G, Barzilay , Greenwald M. Tenfold errors in administration of drug doses: a neglected iatrogenic disease in pediatrics. Pediatrics. 1986;177:848–849
  33. Jaanus SD. Pediatric pharmacology. In:  Rosenbloom AA,  Morgan MW editor. Principles and practice of pediatric optometry. Philadelphia: JB Lippincott Co; 1990;p. 293–312
  34. Mitchell A. (2001) Challenges in pediatric pharmacology: minimizing medication errors. Medscape Pharmacists 2 (10). http://www.medscape.com/viewarticle/421220. Last accessed September 28, 2003.
  35. The eye in childhood. Chicago: Yearbook Medical Publishers, Inc, 1967.
  36. In:  Liebman SD,  Gellis SS editor. Pediatric ophthalmology. St Louis: CV Mosby Co; 1966;
  37. Palmer EA. How safe are ocular drugs in pediatrics?. Ophthalmology. 1984;91:1361–1363
  38. Patton TF, Robinson JR. Pediatric considerations in ophthalmology. J Pediatr Ophthalmol. 1976;13:171–178
  39. Havener WH. Ocular pharmacology. 4th ed. St Louis: CV Mosby; 1978;218-61
  40. Abelson MB, Paradis A, Grant KK. How to prescribe for the smallest sufferers. Rev Ophthalmol. 1999;6(2):101–103
  41. Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. Trans Am Ophthalmol Soc. 1976;74:457–487
  42. Zimmerman TJ, Kooner KS, Kandarakis AS, et al. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102:551–553
  43. Barlett JD, Wesson MD, Swiatochoa , et al. Efficacy of a pediatric cycloplegic administration as a spray. J AM OPTOM ASSOC. 1993;64:617–621
  44. Ismail EE, Rouse MW, De Land PN. A comparison of drop instillation and spray application of 1% cyclopentolate. Optom Vis Sci. 1994;71:235–241
  45. Benavides JO, Satchell ER, Frantz KA. Efficacy of a mydriatic spray in the pediatric population. Optom Vis Sci. 1997;74:160–163
  46. Doe EA, Campagna JA. Pilocarpine spray: an alternative delivery method. J Ocul Pharmacol Ther. 1998;14:1–4
  47. Akman A, Aydin P. Comparison of mydriatic efficacy of spray instillation and drop instillation of tropicamide 1%. Eye. 1999;13:653–655
  48. Passo MS, Palmer EA, van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361–1363
  49. Nagataki S, Mishima S. Pharmacokinetics of instilled drugs in the human eye. Int Ophthalmol Clin. 1980;20(3):33–49
  50. Maurice DM. Factors influencing the penetration of topically applied drugs in the human eye. Int Ophthalmol Clin. 1980;20:21–32
  51. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207–218
  52. Chrai SS, Patton TF, Mehta A, et al. Lacrimal and instilled fluid dynamics in rabbit eyes. J Pharm Sci. 1973;62:1112–1121
  53. Brown RH, Hotchkiss ML, Davis EB. Creating smaller eyedrops by reducing eyedropper tip dimensions. Am J Ophthalmol. 1985;99:460–464
  54. Brown RH, Wood TS, Lynch MG, et al. Improving the therapeutic index of topical phenylephrine by reducing drop volume. Ophthalmology. 1987;94(7):847–850
  55. Lynch MG, Reay HB, Goode SM, et al. Reduction of phenylephrine size in infants achieves equal dilation with decreased systemic absorption. Arch Ophthalmol. 1987;105:1364–1365
  56. Wheatcroft S, Sharma A, McAllister J. Reduction in mydriatic drop size in premature infants. Br J Ophthalmol. 1993;77:364–365
  57. Walson PD, Getschman S, Koren G. Principles of drug prescribing in infants and children. A practical guide. Drugs. 1993;46(2):281–288
  58. Connor JD. A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule. Pediatrics. 1999;104(3):610–613
  59. Wilson RP. Lee DA, Netland PA, eds. The changing face of pediatric glaucomas. Rev Ophthalmol 2002;9(10):97-106.

PII: S1529-1839(04)70157-8

doi: 10.1016/S1529-1839(04)70157-8

Optometry - Journal of the American Optometric Association
Volume 75, Issue 7 , Pages 419-429 , July 2004

Article Tools